Lupin Share Price Trading Near its Current Month High

The 7th Wonder of Pharma Sector

Lupin Limited is Indias seventh largest Pharmaceutical Company in terms of market
capitalization and the fifth largest in the United States by prescription led market share. The
advent of the 21st century ushered the need for companies with solid values and strong vision
in the pharmaceutical industry. Following the traditional path of economics where demand
creates supply, Lupin Ltd. has emerged as the best fit with a vision to excel beyond the realm of
economic cycles, competition, and eventually beyond lifetimes and generations. As the
Founding Chairman cites, that it is the Lupin Spirit which has aided the Pharma Giant innovate
and deliver excellent performance consistently year after year. Unending innovation and
competitive edge has kept Lupin a step ahead of its peers in the modern day business
environment.

A Global Player
A company that envelopes the entire pharmaceutical value chain, Lupins Indian branch caters
to Chronic disease and Lifestyle therapies in the areas of Cardiology, Neurology and Diabetes.
Its European equivalent focuses on opportunities and developments in Oral Contraceptives,
Ophthalmology and Dermatology. In the US, the company works on Pediatric segments and CVS
where 28 out of its 77 products dominate the market.

The India Story

India plays an intrinsic role in the ambitious growth plans of Lupin by contributing as much as
24 per cent of the Companys total global revenues. The Indian markets have been the vital cog
in Lupins resilient revenue figures of Rs. 30,295 million which reflected an impressive growth of
20.5 per cent in FY15 against an industrial growth of 12.1 per cent. Currently, Lupin share price
stands at Rs. 1,530.90. Over the last four years Lupins CAGR stood at 18 per cent where
Chronic therapies contributed to 66 per cent of the total revenues generated in the Indian
subcontinent. The company continues to rule the Anti- TB market and is currently the third
largest player in Cardiology and Anti Asthma segments.
Reading between Price and Product
In FY15, Lupin initiated phase-1 clinical studies for 4 of its products and filed 18 ANDAs
including 5 First-to-File products with USFDA. Later on, the company received approvals from
FDA for 12 of its ANDAs while the cumulative ANDA stands at 210.
The Pharma Giant appears all set to make an everlasting impression on the global arena with
ICRA assigning ICRAA1+ for Lupins short term credit facilities.

Disclaimer
The investment advice or guidance provided by way of recommendations, reports or other
ways are solely the personal views of the research team. Users are advised to use the data for
the purpose of information and rely on their own judgment while making investment decision.
Dynamic Equities Pvt. Ltd - SEBI Investment Advisory Reg. No.: INA300002022
Disclosure
Dynamic Equities Pvt. Ltd. is a member of NSE, BSE, MCX SX and a DP with NSDL & CDSL. It is
also engaged in Investment Advisory Services and Portfolio Management Services. Dynamic
Commodities Pvt. Ltd., associate company, is a member of MCX & NCDEX. We declare that our
activities were neither suspended nor we have defaulted with any stock exchange authority
with whom we are registered. SEBI, Exchanges and Depositories have conducted the routine
inspection and based on their observations have issued advise letters or levied minor penalty
on for certain operational deviations.
Answers to the Best of our knowledge and belief of Dynamic/ its Associates/ Research Analyst:
DYNAMIC/its Associates/ Research Analyst/ his Relative:

Do not have any financial interest / any actual/beneficial ownership in the subject
company.

Do not have any other material conflict of interest at the time of publication of the
research report

Have not received any compensation from the subject company in the past twelve
months

Have not managed or co-managed public offering of securities for the subject company.

Have not received any compensation for brokerage services or any products / services
or any compensation or other benefits from the subject company, nor engaged in
market making activity for the subject company

Have not served as an officer, director or employee of the subject company

Article Written By:

Shivaji Ghata